Role of orexin in the pathophysiology of depression: Potential for pharmacological intervention

CNS Drugs

Volumn 27, Issue 6, 2013, Pages 411-422

  Nollet, Mathieu ^a,b,c   Leman, Samuel ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; CITALOPRAM; CLOMIPRAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; KOSOSAN; MILNACIPRAN; MONOAMINE; NEUROPEPTIDE Y; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PLANT MEDICINAL PRODUCT; SERTRALINE; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; BIPOLAR DEPRESSION; CALORIC RESTRICTION; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CEREBROSPINAL FLUID; CHRONIC STRESS; CIRCADIAN RHYTHM; CORTICOSTEROID BLOOD LEVEL; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE SEVERITY; DNA METHYLATION; DORSAL RAPHE NUCLEUS; EMOTION; FEEDING BEHAVIOR; HIPPOCAMPUS; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIMBIC SYSTEM; LOCUS CERULEUS; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOTHERAPY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REM SLEEP DEPRIVATION; SEASONAL AFFECTIVE DISORDER; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SLEEP TIME; SOCIAL INTERACTION; SUICIDE ATTEMPT; THALAMUS; TREATMENT DURATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; OREXIN RECEPTORS; SIGNAL TRANSDUCTION;

EID: 84879312323     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0064-z     Document Type: Article

References (106)

1. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
2. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34(1):13-25.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498- 504.
5. Kessler RC. The costs of depression. Psychiatr Clin N Am. 2012;35(1):1-14.
6. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9(2):87-98.
7. Fava GA, Offidani E. The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1593-602.
8. Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr. 2009;14(12 Suppl 12):8-14.
9. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.
10. Naudet F, Maria AS, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One. 2011;6(6):e20811.
11. Belzung C, Yalcin I, Griebel G, et al. Neuropeptides in psychiatric diseases: an overview with a particular focus on depression and anxiety disorders. CNS Neurol Disord Drug Targets. 2006;5(2):135-45.
12. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides. 2010;31(4):736-56.
13. Hokfelt T, Broberger C, Xu ZQ, et al. Neuropeptides: an overview. Neuropharmacology. 2000;39(8):1337-56.
14. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322-7.
15. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-85.
16. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996- 10015.
17. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6-25.
18. Trivedi P, Yu H, MacNeil DJ, et al. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438(1-2):71-5.
19. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl. 2007;433:104-15.
20. Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res. 2010;44(4):242-52.
21. Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci. 2008;10(3):291-9.
22. Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537-55.
23. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-9.
24. Stunkard AJ, Faith MS, Allison KC. Depression and obesity. Biol Psychiatry. 2003;54(3):330-7.
25. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2012;9(6):1497-507.
26. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev. 2009;29(7):573-85.
27. Marazziti D, Consoli G, Picchetti M, et al. Cognitive impairment in major depression. Eur J Pharmacol. 2010;626(1):83-6.
28. Murrough JW, Iacoviello B, Neumeister A, et al. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96(4):553-63.
29. Anacker C, Zunszain PA, Carvalho LA, et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 2011;36(3):415-25.
30. Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008;57(2):531-53.
31. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):435-51.
32. Jabbi M, Korf J, Ormel J, et al. Investigating the molecular basis of major depressive disorder etiology: a functional convergent genetic approach. Ann N Y Acad Sci. 2008;1148:42-56.
33. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci. 2011;32(8):451-62.
34. Aston-Jones G, Smith RJ, Moorman DE, et al. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology. 2009;56(Suppl 1):112-21.
35. Aston-Jones G, Smith RJ, Sartor GC, et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res. 2010;1314:74-90.
36. Thompson JL, Borgland SL. A role for hypocretin/orexin in motivation. Behav Brain Res. 2011;217(2):446-53.
37. Di Sebastiano AR, Coolen LM. Orexin and natural reward: feeding, maternal, and male sexual behavior. Prog Brain Res. 2012;198:65-77.
38. Cason AM, Smith RJ, Tahsili-Fahadan P, et al. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav. 2010;100(5):419-28.
39. Karnani M, Burdakov D. Multiple hypothalamic circuits sense and regulate glucose levels. Am J Physiol Regul Integr Comp Physiol. 2011;300(1):R47-55.
40. Di Sebastiano AR, Yong-Yow S, Wagner L, et al. Orexin mediates initiation of sexual behavior in sexually naive male rats, but is not critical for sexual performance. Horm Behav. 2010;58(3):397-404.
41. Di Sebastiano AR, Wilson-Perez HE, Lehman MN, et al. Lesions of orexin neurons block conditioned place preference for sexual behavior in male rats. Horm Behav. 2011;59(1):1-8.
42. Akbari E, Naghdi N, Motamedi F. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides. 2007;28(3):650-6.
43. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239-47.
44. Winsky-Sommerer R, Yamanaka A, Diano S, et al. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci. 2004;24(50):11439-48.
45. Lopez M, Tena-Sempere M, Dieguez C. Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). Front Neuroendocrinol. 2010;31(2):113-27.
46. Spinazzi R, Andreis PG, Rossi GP, et al. Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev. 2006;58(1):46-57.
47. Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29(10):571-7.
48. Estabrooke IV, McCarthy MT, Ko E, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 2001;21(5):1656-62.
49. Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med. 2010;16(1):111-5.
50. Johnson PL, Samuels BC, Fitz SD, et al. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Physiol Behav. 2012;107(5):733-42.
51. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96-104.
52. Grady SP, Nishino S, Czeisler CA, et al. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep. 2006;29(3):295-7.
53. Brundin L, Petersen A, Bjorkqvist M, et al. Orexin and psychiatric symptoms in suicide attempters. J Affect Disord. 2007;100(1-3):259-63.
54. Brundin L, Bjorkqvist M, Petersen A, et al. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007;17(9):573-9.
55. Brundin L, Bjorkqvist M, Traskman-Bendz L, et al. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. J Affect Disord. 2009;113(1-2):179-82.
56. Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's disease. Brain. 2008;131(Pt 1):e88.
57. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain. 2008;131(Pt 1):e87.
58. Palhagen S, Qi H, Martensson B, et al. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol. 2010;257(4):524-32.
59. Rainero I, Ostacoli L, Rubino E, et al. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011;130(3):487-91.
60. Rotter A, Asemann R, Decker A, et al. Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. J Affect Disord. 2011;131(1-3):186-92.
61. von der Goltz C, Koopmann A, Dinter C, et al. Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Horm Behav. 2011;60(5):644-50.
62. Schmidt FM, Brugel M, Kratzsch J, et al. Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett. 2010;483(1):20-2.
63. Schmidt FM, Arendt E, Steinmetzer A, et al. CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res. 2011;190(2-3):240-3.
64. Allard JS, Tizabi Y, Shaffery JP, et al. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides. 2004;38(5):311-5.
65. Taheri S, Gardiner J, Hafizi S, et al. Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats. Neuroreport. 2001;12(3):459-64.
66. Mikrouli E, Wortwein G, Soylu R, et al. Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides. 2011;45(6):401-6.
67. Hemmeter UM, Hemmeter-Spernal J, Krieg JC. Sleep deprivation in depression. Expert Rev Neurother. 2010;10(7):1101-15.
68. Allard JS, Tizabi Y, Shaffery JP, et al. Effects of rapid eye movement sleep deprivation on hypocretin neurons in the hypothalamus of a rat model of depression. Neuropeptides. 2007;41(5):329-37.
69. Feng P, Vurbic D, Wu Z, et al. Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res. 2007;1154:163-72.
70. Feng P, Vurbic D, Wu Z, et al. Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. J Psychopharmacol. 2008;22(7):784-91.
71. Mori T, Ito S, Kuwaki T, et al. Monoaminergic neuronal changes in orexin deficient mice. Neuropharmacology. 2010;58(4-5):826-32.
72. Muraki Y, Yamanaka A, Tsujino N, et al. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci. 2004;24(32):7159-66.
73. Yamanaka A, Muraki Y, Ichiki K, et al. Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. J Neurophysiol. 2006;96(1):284-98.
74. Feng P, Hu Y, Li D, et al. The effect of clomipramine on wake/sleep and orexinergic expression in rats. J Psychopharmacol. 2009;23(5):559-66.
75. Nocjar C, Zhang J, Feng P, et al. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138-53.
76. Lutter M, Krishnan V, Russo SJ, et al. Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci. 2008;28(12):3071-5.
77. Mahler SV, Smith RJ, Moorman DE, et al. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res. 2012;198:79-121.
78. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805-9.
79. Surget A, Tanti A, Leonardo ED, et al. Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry. 2011;16(12):1177-88.
80. Ito N, Yabe T, Gamo Y, et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience. 2008;157(4):720-32.
81. Howell OW, Doyle K, Goodman JH, et al. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem. 2005;93(3):560-70.
82. Ito N, Yabe T, Nagai T, et al. A possible mechanism underlying an antidepressive-like effect of Kososan, a Kampo medicine, via the hypothalamic orexinergic system in the stress-induced depression-like model mice. Biol Pharm Bull. 2009;32(10):1716-22.
83. Adidharma W, Leach G, Yan L. Orexinergic signaling mediates light-induced neuronal activation in the dorsal raphe nucleus. Neuroscience. 2012;220:201-7.
84. Pail G, Huf W, Pjrek E, et al. Bright-light therapy in the treatment of mood disorders. Neuropsychobiology. 2011;64(3):152-62.
85. Surget A, Belzung C. Unpredictable chronic mild stress in mice. In: Kalueff AV, LaPorte JL, editors. Experimental animal models in neurobehavioral research. New York: Nova Science Publishers; 2009. p. 79-112.
86. Nollet M, Gaillard P, Minier F, et al. Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology. 2011;61(1-2):336-46.
87. Nollet M, Gaillard P, Tanti A, et al. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology. 2012;37(10):2210-21.
88. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron. 2010;65(1):7-19.
89. Harald B, Gordon P. Meta-review of depressive subtyping models. J Affect Disord. 2012;139(2):126-40.
90. Pae CU, Tharwani H, Marks DM, et al. Atypical depression: a comprehensive review. CNS Drugs. 2009;23(12):1023-37.
91. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci. 2001;14(7):1075-81.
92. Adda C, Lefevre B, Reimao R. Narcolepsy and depression. Arq Neuropsiquiatr. 1997; 55(3A):423-6.
93. Fortuyn HA, Lappenschaar MA, Furer JW, et al. Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry. 2010;32(1):49-56.
94. Reynolds CF III, Christiansen CL, Taska LS, et al. Sleep in narcolepsy and depression. Does it all look alike? J Nerv Ment Dis. 1983;171(5):290-5.
95. Vourdas A, Shneerson JM, Gregory CA, et al. Narcolepsy and psychopathology: is there an association? Sleep Med. 2002;3(4):353-60.
96. Kornum BR, Faraco J, Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol. 2011;21(6):897-903.
97. Bayard S, Abril B, Yu H, et al. Decision making in narcolepsy with cataplexy. Sleep. 2011;34(1):99-104.
98. Dimitrova A, Fronczek R, Van der Ploeg J, et al. Reward-seeking behavior in human narcolepsy. J Clin Sleep Med. 2011;7(3):293-300.
99. Jara CO, Popp R, Zulley J, et al. Determinants of depressive symptoms in narcoleptic patients with and without cataplexy. J Nerv Ment Dis. 2011;199(5):329-34.
100. Dodel R, Peter H, Spottke A, et al. Health-related quality of life in patients with narcolepsy. Sleep Med. 2007;8(7-8):733-41.
101. Fortuyn HA, Mulders PC, Renier WO, et al. Narcolepsy and psychiatry: an evolving association of increasing interest. Sleep Med. 2011;12(7):714-9.
102. Scott MM, Marcus JN, Pettersen A, et al. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res. 2011;222(2):289-94.
103. Johnson PL, Samuels BC, Fitz SD, et al. Activation of the orexin 1 receptor is a critical component of CO(2)-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology. 2012;37(8):1911-22.
104. Rolls A, Colas D, Adamantidis A, et al. Optogenetic disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci USA. 2011;108(32):13305-10.
105. Steiner MA, Sciarretta C, Brisbare-Roch C, et al. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology. 2013;38(4):560-71.
106. Guo Y, Feng P. OX2R activation induces PKC-mediated ERK and CREB phosphorylation. Exp Cell Res. 2012;318(16):2004-13.